Abstract
Inflammatory bowel disease (IBD) is a complex, chronic, and dysregulated inflammatory condition which etiology is still largely unknown. Its prognosis and disease progression are highly variable and unpredictable. IBD comprises several heterogeneous inflammatory conditions ranging from Ulcerative Colitis (UC) to Crohn’s Disease (CD). Importantly, a definite, well-established, and effective clinical treatment for these pathologies is still lacking. The urgent need for treatment is further supported by the notion that patients affected by UC or CD are also at risk of developing cancer. Therefore, a deeper understanding of the molecular mechanisms at the basis of IBD development and progression is strictly required to design new and efficient therapeutic regimens. Although the development of animal models has undoubtedly facilitated the study of IBD, such in vivo approaches are often expensive and time-consuming. Here we propose an organ ex vivo culture (Gut-Ex-Vivo system, GEVS) based on colon from Balb/c mice cultivated in a dynamic condition, able to model the biochemical and morphological features of the mouse models exposed to DNBS (5–12 days), in 5 h. Indeed, upon DNBS exposure, we observed a dose-dependent: (i) up-regulation of the stress-related protein transglutaminase 2 (TG2); (ii) increased intestinal permeability associated with deregulated tight junction protein expression; (iii) increased expression of pro-inflammatory cytokines, such as TNFα, IFNγ, IL1β, IL6, IL17A, and IL15; (iv) down-regulation of the anti-inflammatory IL10; and (v) induction of Endoplasmic Reticulum stress (ER stress), all markers of IBD. Altogether, these data indicate that the proposed model can be efficiently used to study the pathogenesis of IBD, in a time-and cost-effective manner.
| Original language | English |
|---|---|
| Article number | 605 |
| Journal | Biology |
| Volume | 10 |
| Issue number | 7 |
| DOIs | |
| State | Published - 30 Jun 2021 |
Bibliographical note
Publisher Copyright:© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Funding
Funding: This work was supported by the Italian Ministry of Education, University and Research (MIUR) program “Departments of Excellence 2018-2022”, FOHN Project—Department of Health Sciences, Università del Piemonte Orientale. The support of FAR 2019 (Progetti di Ateneo), the EU grant “PREMUROSA” (ID#860462), and “ExcellMater” (ID #952033) H2020 projects are also acknowledged. E.P. was supported by H2020 EU grant (PREMUROSA). N.Y. was supported by the Israel Science Foundation (grant No. 3114831), the Israel Science Foundation—Broad Institute Joint Program (grant No. 8165162), and the Gassner fund for medical research, Israel.
| Funders | Funder number |
|---|---|
| Broad Institute Joint Program | 8165162 |
| Department of Health Sciences | |
| Gassner Fund for Medical Research, Israel | |
| H2020 EU | |
| Horizon 2020 Framework Programme | 860462, 952033 |
| European Commission | |
| Ministero dell’Istruzione, dell’Università e della Ricerca | |
| Israel Science Foundation | 3114831 |
| Università degli Studi del Piemonte Orientale |
Keywords
- DNBS
- Ex vivo organ
- IBD
- Tissue culture
- UPR